RF Lesion Monitoring With 8mm IntellaTip MiFi XP
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02089672 |
Recruitment Status :
Completed
First Posted : March 18, 2014
Last Update Posted : November 17, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Abnormal heart rhythms or arrhythmias are often managed by a procedure in which a catheter is introduced into the heart. These catheters can then cauterize abnormally functioning portions of the heart muscle with the hope of returning the heart to a more effective rhythm. In the process of performing such a procedure, called a catheter ablation, an operator must be able to accurately sense electrical activity displayed on computer screens in different parts of the heart, provide sufficient localized energy to the abnormally behaving tissue (ideally without damaging uninvolved heart structures), and accurately reassess the electrical activity of the heart to ensure the spot in the heart has been cauterized.
When sensing electrical activity of the heart, specialized catheters produce recordings on a computer screen known as electrograms (EGM). To produce this recording conventional catheters commonly use a positive and negative electrode, from which the difference between the two provides the EGM. The distance between the two electrodes varies from device to device. The greater the distance between them, the less accurate the measurement of local electrical activity becomes. This may result in poorly localized or excessive use of energy that could be damaging to normal heart structures or put the patient at risk for the return or development of additional arrhythmias. The IntellaTip MiFi catheter has been constructed with a specialized sensing tip that uses "microelectrodes" that are relatively close in proximity (<1 mm apart) with the hope of improving the sensing capability of the device.
This study will analyze the signals obtained from this FDA-approved catheter in people undergoing a catheter ablation procedure. The study will examine signals after the procedure is finished and will not prolong or differ the process from a standard ablation procedure. The goal of this study is to determine the ability of the microelectrodes to distinguish ablated, or cauterized versus non-cauterized tissue.
Condition or disease | Intervention/treatment |
---|---|
Atrial Flutter Arrhythmia | Device: Catheter ablation |
Study Type : | Observational |
Actual Enrollment : | 30 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Radiofrequency Ablation Lesion Monitoring Using Imbedded Micro-Electrodes Versus Standard Bipolar Electrograms |
Study Start Date : | April 2014 |
Actual Primary Completion Date : | November 2015 |
Actual Study Completion Date : | November 2015 |
Group/Cohort | Intervention/treatment |
---|---|
Atrial flutter patients
Atrial flutter patients undergoing catheter ablation
|
Device: Catheter ablation
This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
Other Name: 8mm IntellaTip MiFi XP ablation catheter |
- Total bipolar electrogram amplitude using tip to ring and pin to pin configurations [ Time Frame: Acute, averaged one hour during ablation. Measured postoperatively. ]
- Total number of seconds per isthmus ablation spent in excess of the post-hoc identified complete lesion time. [ Time Frame: Acute, averaged one hour during ablation. Measured postoperatively ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Any adult undergoing an atrial flutter ablation
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089672
United States, Georgia | |
Emory University Hospital | |
Atlanta, Georgia, United States, 30322 |
Principal Investigator: | Michael Lloyd, MD FHRS FACC | Emory University |
Publications:
Responsible Party: | Michael S. Lloyd, Principal investigator, Emory University |
ClinicalTrials.gov Identifier: | NCT02089672 |
Other Study ID Numbers: |
IRB00069674 ISRCRM90003 ( Other Identifier: Other ) |
First Posted: | March 18, 2014 Key Record Dates |
Last Update Posted: | November 17, 2015 |
Last Verified: | November 2015 |
Atrial Flutter Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |